Quick Takeaways: Why It Matters? Zoetis’s Portela launch should expand the feline OA market by turning a hard-to-manage, underdiagnosed condition into a more actionable treatment segment, especially because the therapy offers a three-month injectable option that is easier for owners to kee...
Quick Takeaways: Why It Matters? Gallant’s positive UMSC pilot data and FDA CVM’s expanded conditional approval eligibility together position this program as a potential first‑in‑class, disease‑modifying biologic in an almost empty feline OA toolbox. By showing up to...
